CAR T-cells are autologous T-cells transduced with a chimeric antigen receptor 
which targets the modified T-cell against a specified cancer antigen. Anti-CD19 
CAR T-cells currently represent transformational therapy for relapsed/refractory 
aggressive B-cell lymphomas where durable remissions can be induced in patients 
with previously incurable chemotherapy-refractory disease. Three anti-CD19 CAR 
T-cells are currently Food and Drug Administration and European Medicines Agency 
approved or in advanced-stage development: axicabtagene ciloleucel, 
tisagenlecleucel, and lisocabtagene maraleucel. Although all targeting CD19 on 
the surface of malignant (and healthy) B-cells, these products differ from one 
another in multiple ways including construct, manufacturing, dose, design of 
pivotal clinical trials, and toxicity profile. Efficacy and safety data for 
anti-CD19 CAR T-cell therapy in aggressive B-cell lymphomas will be reviewed, as 
well as novel CAR T-cell designs and strategies for overcoming treatment 
resistance.